Article Figures & Data
Tables
- Table 1.
Factors associated with inflammatory bowel disease (IBD) at baseline (univariable analysis).
Variables IBD+ vs IBD−, Prevalent M0 OR (95% CI) or mean (SD) p HLA-B27 0.47 (0.21–0.98) 0.03 mNY criteria at M0 2.28 (0.94–5.12) 0.05 Uveitis history 3.80 (1.49–8.90) 0.003 Familial history of IBD 3.97 (1.11–11.57) 0.02 Psoriasis 0.09 (0.02–0.24) < 0.0001 DMARD use 3.74 (1.63–8.19) < 0.001 Steroid use 4.21 (1.83–9.25) < 0.001 NSAID score at 6 mos 30.2 (36.0) vs 45.5 (40.5) 0.005 Sick leave, days 33.9 (49.3) vs 32.7 (69.1) 0.09 ESR, mm/h 22.6 (26.7) vs 13.3 (14.5) 0.04 Hemoglobin, g/dl 15.7 (19.0) vs 16.0 (18.0) 0.02 M0: Month 0; mNY: modified New York criteria; DMARD: disease-modifying antirheumatic drug; NSAID: nonsteroidal antiinflammatory drug; ESR: erythrocyte sedimentation rate.
- Table 2.
Factors associated with inflammatory bowel disease (IBD) at the 5-year visit (M60; univariable analysis).
Variables IBD+ vs IBD−, Prevalent M60 OR (95% CI) or mean (SD) p DMARD use 2.58 (1.35–5.08) 0.002 NSAID score at 6 months 17.00 (31.20) vs 19.87 (30.37) 0.03 Sick leave, days 20.80 (59.16) vs 11.35 (39.19) 0.03 Anti-TNF useV(yes/no) 2.11 (1.06–4.31) 0.02 ASDAS CRP 2.28 (0.85) vs 2.02 (0.83) 0.03 BASFI 29.04 (20.14) vs 22.08 (21.18) 0.02 SF-36 physical 39.26 (9.91) vs 43.59 (9.60) 0.004 SF-36 mental 41.2 (11.62) vs 45.2 (11.06) 0.013 HAQ 0.75 (0.58) vs 0.50 (0.51) 0.004 ASQoL 8.72 (5.65) vs 6.59 (5.37) 0.012 No. tender joints 5.84 (9.77) vs 2.37 (5.80) 0.009 M60: Month 60; DMARD: disease-modifying antirheumatic drug; NSAID: nonsteroidal antiinflammatory drug; anti-TNF: anti-tumor necrosis factor; ASDAS: Ankylosing Spondylitis Disease Activity Score; CRP: C-reactive protein; BASFI: Bath Ankylosing Spondylitis Functional Index; SF-36: Medical Outcomes Study Short Form-36 questionnaire; HAQ: Health Assessment Questionnaire; ASQoL: Ankylosing Spondylitis Quality of Life score.
- Table 3.
Baseline factors associated with incidence of new cases of inflammatory bowel disease (IBD) between baseline and 5 years (univariable analysis).
Variables IBD+ vs IBD− OR (95% CI) or mean (SD) p mNY criteria at M0 2.58 (0.88–6.81) 0.006 Familial history of IBD 3.97 (0.92–13.02) 0.032 Psoriasis 0 (0–0.73) 0.013 SF-36 physical 36.75 (8.75) vs 40.34 (9.04) 0.047 mNY: modified New York criteria; M0: Month 0; SF-36: Medical Outcomes Study Short Form-36 questionnaire.
In this issue
